ClinicalTrials.gg
Not yet recruitingNCT07888686Updated Nov 6, 2026

Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine

A Phase 1/2 interventional study of 10vHPV and Gardasil9 in Human Papillomavirus Infection, sponsored by Serum Institute of India Pvt. Ltd.. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Serum Institute of India Pvt. Ltd. · Phase 1/2, Interventional, and Prevention

How we know

Updated Nov 6, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Papillomavirus Infections with a site in Australia — 3 open to participants now, 3 under way, none of them phase 3. Papillomavirus Infections · Australia.

Planned enrollment
8th of 11
72 · median 199
Started
2026
the only one that year
Phase 1/2
2 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Serum Institute of India Pvt. Ltd.

Among the 14 studies in Papillomavirus Infections with a site in Australia, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 1/2, and was the 14th registered.

Papillomavirus Infections

581 studies on the registry are indexed under Papillomavirus Infections; 135 are open to participants now.

Browse Papillomavirus Infections studies →

Open to participants now

3 of the 14 studies in Papillomavirus Infections with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 89 Papillomavirus Infections studies recruiting now, 40 (45%) set no upper age limit and 44 (49%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Papillomavirus Infections with a site in Australia, or all of them as a file.
02

Study summary

Human papilloma virus (HPV) is the most common viral infection of the reproductive system and is spread through contact with infected genital skin, mucous membranes, or bodily fluids. This study will assess an experimental vaccine called 10 valent Human Papillomavirus Virus (10vHPV) for the safety, reactivity, and immune response, in healthy adults, compared to Gardasil 9.

There are two phases in this study - Phase 1 will include up to 36 healthy adults aged 18-25 years, Phase 2 will include 36 healthy adults aged 26-45 years. Participants will be randomised in a 2-to-1 ratio to receive either 10vHPV or Gardasil 9.

10vHPV or Gardasil 9 will be administered as a 0.5 mL single dose via intramuscular injection in the deltoid muscle of the upper arm. In Phase 1, participants will receive a single dose on Day 1, and in Phase 2, participants will receive a single dose on Day 1, 2 months, and 6 months.

03

Conditions studied

  • Human Papillomavirus Infection

Keywords

  • HPV
  • Vaccine
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 18 to 25 years inclusive at Screening (Phase 1 Only)
  • Males and females aged 26 to 45 years inclusive at Screening (Phase 2 Only)
  • Willing and able to sign an Form (ICF)
  • Good physical and mental health based on medical history, physical examination, clinical laboratory, (ECG), and vital signs, as judged by the Investigator
  • Participants willing and able to comply with the requirements of the Protocol
  • Participants agree to refrain from strenuous exercise (including weightlifting) within 96 hours (4 days) prior to Screening, and each day of vaccine administration
  • Willing and able to comply with restrictions of nicotine use throughout the study is not permitted from within 48 hours [2days] prior to Screening, from Day 1 until Day 8, and within 48 hours [2 days] prior to the end of study [EoS/early termination [ET} visit)
  • Male participants, if not surgically sterilised or have partners of the same sex, must agree to use highly effective and not plan a pregnancy or donate sperm from Day 1 until 90 days after the last study visit.
  • Female participants of who have fertile male sexual partners must agree to use highly effective contraception from Day 1 until 90 days after the last study visit.

Exclusion criteria

Exclusion Criteria:

  • Positive drug and/or alcohol screen at Screening and Day 1 (Phase 1 Only)
  • Are vaccinated against HPV
  • History of HPV infection and associated medical conditions (confirmed either clinically, serologically, or microbiologically) including history of abnormal Papanicolau test, HPV DNA test, abnormal cervical ,or external genital warts, as reported by the participant
  • History of administration of any or non-registered product (drug or vaccine) 30 days prior to study vaccine administration on Day 1 or plan to participate in another study with investigational drug or vaccine prior to Day 30
  • Any vaccination received 30 days before Screening or plan to receive a vaccination between Screening and Day 30
  • Pregnant or lactating females or females planning to become pregnant or beast feed during the study
  • Any findings on medical examination deviating from normal and assessed as by the investigator
  • A participant who has a (BMI) >35.0 kg/m2
  • A participant who has skin markings in both deltoid areas, which prevents injection site reaction (ISR)assessment, in the opinion of the investigator
  • History of alcohol abuse or drug addiction
  • Positive screen for , HBcAb, antibodies, or 1 and 2 antibodies
  • History of a severe allergic reaction (e.g. anaphylaxis) after any vaccine or to any component (active substances or ) of the study vaccines
  • History of major congenital defects or developmental disorders or genetic diseases as determined by medical history or clinical assessment
  • History of thrombocytopenia or a bleeding disorder following an IM injection
  • History or current evidence of any condition or therapy which might interfere with the participant's participation for the full duration of the study, evidence of suspected diseases, or is not in the best interest of the participants to participate, in the opinion of the investigator
  • History of major surgery =30 days prior to study vaccination on Day 1. If the participant has had any surgery >30 days prior to the study vaccination on Day 1, the participant can be enrolled in the study at the discretion of the investigator
  • Acute illness (moderate or severe) and/or fever (tympanic) (temperature ≥38.0°C) at the time of vaccination or during the 72 hours prior to the vaccination on Visit 2 (Day 1) should be delayed until the participant is fully recovered and fever-free
  • History of receipt of a blood transfusion, other blood products, or immunoglobulins in 3 months prior to study vaccination, or planned receipt of blood products during the study period.
  • Any confirmed or suspected congenital or acquired , immunodeficient condition or disease, based on medical history and physical examination.
  • Family history of any medical conditions, that in the Investigator's opinion, could affect the trial outcomes.
  • Chronic administration (defined as >14 days) of immunosuppressant or other immune modifying drugs(including topical calcineurin inhibitors) during the period starting 6 months prior to the study vaccine administration or planned during the study period up to Visit 4 (Day 30 [-2 to +14 days]).
  • Any plans to permanently relocate from the area prior to the completion of the study or to leave for an extended period of time when study visits would be scheduled.
  • Employee of any organisation associated with this study.
  • History of clinically relevant drug and/or food allergies.
  • History of alcohol consumption of more than 10 standard drinks/week and no more than 4 standard drinks on any one day within 3 months prior to Screening.
  • Any physical, psychological, mental and/or social reason which in the opinion of the Investigator makes the participant unsuitable for the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    10vHPV Vaccine

    Biological: 10vHPV

  • Active comparator
    Gardasil9

    Biological: Gardasil9

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the safety and reactogenicity of a single dose of 10vHPV vaccine in comparison with a single dose of Gardasil 9 vaccine in healthy adults aged 18 to 25 years in phase 1.

    The incidence, severity and relationship of solicited AEs during 7-day, unsolicited and serious adverse events during 30-day follow-up period after administration of a single dose.

    Time frame: 30 days after vaccination

  2. To assess the safety of 3 doses (administered at day 0, 60 and 180) of 10vHPV vaccine in comparison with 3 doses (administered at day 0, 60 and 180) of Gardasil 9 vaccine in healthy adults aged 26 to 45 years.

    The incidence, severity and relationship of solicited AEs during 7-day after each vaccine dose, unsolicited and serious adverse events up to 30 days after the last dose .

    Time frame: 30 days after last dose

Secondary outcomes

  1. To assess immune response 30 days after vaccination with 10vHPV vaccine compared to Gardasil 9 in healthy adults aged 18 to 25 years.

    Percentage of participants achieving seroconversion, Geometric mean titres (GMTs) for anti-HPV antibodies, Geometric mean fold rise (GMFR) on Day 30.

    Time frame: 30 days after vaccination

  2. To assess immune response 30 days after 3rd vaccination with 10vHPV vaccine compared to Gardasil 9 in healthy adults aged 26 to 45 years.

    Percentage of participants achieving seroconversion, GMTs for anti-HPV antibodies and GMFR on Day 30 post 3rd dose (Month 7)

    Time frame: 7 months

Other outcomes

  1. To assess immune response 6 months after vaccination with 10vHPV vaccine compared to Gardasil 9 in healthy adults aged 18 to 25 years.

    Percentage of participants achieving seroconversion, GMTs for anti-HPV antibodies, GMFR at Month 6

    Time frame: 6 month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Summary Results

Supporting information: Study protocol

Time frame: 24 month after the study completion

Access criteria: Researchers who provide a methodologically sound proposal may be provided the access afterSponsor permission and if signed data-access agreements are in place.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Feb 2028, 15 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2026
First posted
Oct 22, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Feb 2028
CompletionEst.
Apr 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Nov 2026
Nov 6, 2026
Registered
First appeared on the registry
Oct 22, 2026
Show all 2 updates
  1. Nov 6, 2026
    Start date Oct 2026→Nov 2026
    + 1 other change: verification date
  2. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07888686
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Hitt Sharma
Contact
drhjs@seruminstitute.com
+91-9822418354
Sameer Parekh
Contact
sameer.parekh@seruminstitute.com
+91-9226722745
Hitt Sharma
study director · Serum Institute of India Pvt. Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion